Publications

Detailed Information

The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma

DC Field Value Language
dc.contributor.authorKim, Bomi-
dc.contributor.authorMyung, Jae Kyung-
dc.contributor.authorSeo, Ja Hee-
dc.contributor.authorPark, Chul-Kee-
dc.contributor.authorKim, Dong Gyu-
dc.contributor.authorPark, Sung-Hye-
dc.contributor.authorJung, Hee-Won-
dc.contributor.authorPaek, Sun Ha-
dc.date.accessioned2012-05-31T05:16:13Z-
dc.date.available2012-05-31T05:16:13Z-
dc.date.issued2010-07-15-
dc.identifier.citationJOURNAL OF THE NEUROLOGICAL SCIENCES; Vol.294; 112-118ko_KR
dc.identifier.issn0022-510X-
dc.identifier.urihttps://hdl.handle.net/10371/76672-
dc.description.abstractGlioblastoma (GBM) is a malignant CNS neoplasm. The prognosis of GBM may be influenced by the molecules of p53/MDM2/p14ARF. RB/p16INK4a, and the EGFR/PTEN/protein kinase B (PKB)/phosphoinositide 3-kinase (PI3K) pathways. We studied the expression status of specific molecular markers in GBMs by immunohistochemistry (INC) and FISH in correlation with the clinical outcomes. The positivity of EGFR FISH and those of EGFR IHC by pharmDx and Zymed antibodies were 64.9%, 73.5%, and 43.4%, respectively. EGFR pharmDx antibody was more sensitive but less specific than EGFR Zymed antibody. p53 overexpression. MDM2 expression, p16 loss, PTEN loss, PKB and PI3K expression were found in 48.2%, 26.5%, 56.6%, 21.4%, 15.7% and 6.0%, respectively. EGFR IHC and FISH significantly, although not completely, correlated and EGFR and p53 immunoexpression also showed positive correlation. On multivariate survival studies, old age (>= 40 yrs) and bilaterality were independent unfavorable prognosis factors (p<0.05). Stratified by age, resectability and tumor size <5 cm were favorable survival factors in young (40= 40 yrs), respectively. Furthermore, the patients with supratentorial tumor lived longer than the patients with infratentorial tumor (p<0.05). Longer survival (survival length, years) was statistically less frequent in the patients in the EGFR FISH-positive group (p = 0.031). (C) 2010 Elsevier B.V. All rights reserved.ko_KR
dc.language.isoenko_KR
dc.publisherELSEVIER SCIENCE BVko_KR
dc.subjectGlioblastomako_KR
dc.subjectPrognosisko_KR
dc.subjectEpidermal growth factorko_KR
dc.subjectBrain neoplasmko_KR
dc.subjectTumor suppressor protein p53ko_KR
dc.titleThe clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastomako_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김봄이-
dc.contributor.AlternativeAuthor명재경-
dc.contributor.AlternativeAuthor박철기-
dc.contributor.AlternativeAuthor백선하-
dc.contributor.AlternativeAuthor김동규-
dc.contributor.AlternativeAuthor정희원-
dc.contributor.AlternativeAuthor박성혜-
dc.identifier.doi10.1016/j.jns.2010.03.019-
dc.citation.journaltitleJOURNAL OF THE NEUROLOGICAL SCIENCES-
dc.description.citedreferencePuszynski K, 2008, J THEOR BIOL, V254, P452, DOI 10.1016/j.jtbi.2008.05.039-
dc.description.citedreferenceBuckley AF, 2008, AM J CLIN PATHOL, V129, P245, DOI 10.1309/WF10QAAED3PP93BH-
dc.description.citedreferenceGil-Benso R, 2007, CLIN NEUROPATHOL, V26, P224-
dc.description.citedreferenceBuckley AF, 2007, APPL IMMUNOHISTO M M, V15, P305-
dc.description.citedreferenceOhgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011-
dc.description.citedreferenceLOUIS DN, 2007, WHO CLASSIFICATION T-
dc.description.citedreferenceJeon YK, 2006, LUNG CANCER, V54, P387, DOI 10.1016/j.lungcan.2006.08.015-
dc.description.citedreferencePuputti M, 2006, MOL CANCER RES, V4, P927, DOI 10.1158/1541-7786.MCR-06-0085-
dc.description.citedreferenceNagpal J, 2006, ANTICANCER RES, V26, P4633-
dc.description.citedreferenceKleinschmidt-DeMasters BK, 2006, BRAIN PATHOL, V16, P273-
dc.description.citedreferenceMellinghoff IK, 2005, NEW ENGL J MED, V353, P2012-
dc.description.citedreferenceXie D, 2005, ACTA NEUROPATHOL, V110, P481, DOI 10.1007/s00401-005-1072-y-
dc.description.citedreferenceJoensuu H, 2005, J PATHOL, V207, P224, DOI 10.1002/path.1823-
dc.description.citedreferenceDei Tos AP, 2005, EUR J CANCER, V41, P1383, DOI 10.1016/j.ejca.2005.03.018-
dc.description.citedreferenceCappuzzo F, 2005, J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112-
dc.description.citedreferenceHegi ME, 2005, NEW ENGL J MED, V352, P997-
dc.description.citedreferenceGanigi PM, 2005, PEDIATR NEUROSURG, V41, P292, DOI 10.1159/000088731-
dc.description.citedreferenceMarquez A, 2004, DIAGN MOL PATHOL, V13, P1-
dc.description.citedreferenceKUMAR V, 2004, ROBBINS COTRAN PATHO-
dc.description.citedreferenceHirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069-
dc.description.citedreferenceOkada Y, 2003, CANCER RES, V63, P413-
dc.description.citedreferenceMayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462-
dc.description.citedreferenceSteidl C, 2002, J PATHOL, V198, P115, DOI 10.1002/path.1175-
dc.description.citedreferenceSmith JS, 2001, J NATL CANCER I, V93, P1246-
dc.description.citedreferenceLacroix M, 2001, J NEUROSURG, V95, P190-
dc.description.tc1-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share